[go: up one dir, main page]

TR199901307T2 - Lycotriene antagonists for oral squamous cell carcinoma - Google Patents

Lycotriene antagonists for oral squamous cell carcinoma

Info

Publication number
TR199901307T2
TR199901307T2 TR1999/01307T TR9901307T TR199901307T2 TR 199901307 T2 TR199901307 T2 TR 199901307T2 TR 1999/01307 T TR1999/01307 T TR 1999/01307T TR 9901307 T TR9901307 T TR 9901307T TR 199901307 T2 TR199901307 T2 TR 199901307T2
Authority
TR
Turkey
Prior art keywords
lycotriene
antagonists
oral squamous
cell carcinoma
squamous cell
Prior art date
Application number
TR1999/01307T
Other languages
Turkish (tr)
Inventor
H. Fleisch Jerome
T. Jackson William
S. Sawyer Jason
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of TR199901307T2 publication Critical patent/TR199901307T2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrane Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Bu bulus oral skuamöz karsinomunun tedavisi veya inhibisyonu için, ihtiyaç duyan bir memeliye bir lökotrien B4 antagonisti olarak etkinligine sahip bir bilesigin etkili bir miktarinin verilmesine dayanan yöntemler sunmaktadir.This invention provides methods for the treatment or inhibition of oral squamous carcinoma, based on the provision of an effective amount of a compound that has efficacy as a leukotriene B4 antagonist to a mammal in need.

TR1999/01307T 1996-12-13 1997-12-02 Lycotriene antagonists for oral squamous cell carcinoma TR199901307T2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3426996P 1996-12-13 1996-12-13
US4087497P 1997-03-21 1997-03-21

Publications (1)

Publication Number Publication Date
TR199901307T2 true TR199901307T2 (en) 1999-08-23

Family

ID=26710754

Family Applications (1)

Application Number Title Priority Date Filing Date
TR1999/01307T TR199901307T2 (en) 1996-12-13 1997-12-02 Lycotriene antagonists for oral squamous cell carcinoma

Country Status (14)

Country Link
EP (1) EP0964683A4 (en)
JP (1) JP2001509142A (en)
KR (1) KR20000069452A (en)
CN (1) CN1245429A (en)
AU (1) AU726215B2 (en)
CA (1) CA2274855A1 (en)
EA (1) EA002742B1 (en)
IL (1) IL130304A0 (en)
NO (1) NO992846D0 (en)
NZ (1) NZ335922A (en)
PL (1) PL334241A1 (en)
TR (1) TR199901307T2 (en)
UA (1) UA47505C2 (en)
WO (1) WO1998025615A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001282717A1 (en) 2000-07-28 2002-02-13 Cancer Research Technology Limited Cancer treatment by combination therapy
GB0121285D0 (en) 2001-09-03 2001-10-24 Cancer Res Ventures Ltd Anti-cancer combinations
GB2386836B (en) 2002-03-22 2006-07-26 Cancer Res Ventures Ltd Anti-cancer combinations
GB2394658A (en) 2002-11-01 2004-05-05 Cancer Rec Tech Ltd Oral anti-cancer composition
US8093253B2 (en) * 2008-03-06 2012-01-10 Hoffmann-La Roche Inc. Leukotriene B4 inhibitors
KR101898879B1 (en) 2014-03-05 2018-09-14 재단법인 진안홍삼연구소 A composition comprising the red ginseng extract of postmanufacture for treating or preventing oral squamous cell carcinoma

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6372648A (en) * 1986-09-16 1988-04-02 Sumitomo Pharmaceut Co Ltd Novel unsaturated fatty acid derivative
CZ280135B6 (en) * 1991-11-25 1995-11-15 Eli Lilly And Company Process for preparing diphenyl derivative
PH30449A (en) * 1991-11-25 1997-05-28 Lilly Co Eli Substituted phenyl phenol leukotriene antagonists

Also Published As

Publication number Publication date
JP2001509142A (en) 2001-07-10
EA199900543A1 (en) 2000-02-28
UA47505C2 (en) 2002-07-15
IL130304A0 (en) 2000-06-01
NO992846L (en) 1999-06-11
EP0964683A1 (en) 1999-12-22
CN1245429A (en) 2000-02-23
KR20000069452A (en) 2000-11-25
NZ335922A (en) 2000-12-22
CA2274855A1 (en) 1998-06-18
AU7845198A (en) 1998-07-03
AU726215B2 (en) 2000-11-02
WO1998025615A1 (en) 1998-06-18
EP0964683A4 (en) 2002-08-14
NO992846D0 (en) 1999-06-11
PL334241A1 (en) 2000-02-14
EA002742B1 (en) 2002-08-29

Similar Documents

Publication Publication Date Title
EE200100167A (en) 4-amino-substituted 2-substituted 1,2,3,4-tetrahydroquinolines as CETP inhibitors
BR9810342A (en) New imidazole compounds replaced
DE69917296D1 (en) NEW SUBSTITUTED TRIAZOLE COMPOUNDS
PT998460E (en) NEW TETRAZOLE DERIVATIVES
DK0928362T3 (en) Blocking composition for use in an underground formation
NO20011429L (en) Procedure for adding synthetic grass
EE200100166A (en) 4-Carboxyamino-2-substituted 1,2,3,4-tetrahydroquinolines as CETP inhibitors
TR200100189T2 (en) Anti-inflammatory compounds against cell adhesion
DK0889886T3 (en) Novel, 6-position substituted phenanthridines
TR200002345T2 (en) Glucocorticoid selective anti-inflammatory agents
EA200100732A1 (en) ANTI-INFLAMMATORY AND IMMUNOSUPRESSOR COMPOUNDS INHIBITING CELLULAR ADHESION
ATE510553T1 (en) BETA-2-GLYCOPROTEIN 1 AS ANGIOGENESIS INHIBITOR
MY129445A (en) Compositions for treating inflammatory response
EE200100039A (en) Phthalazine derivatives as phosphodiesterase-4 inhibitors
HUP9904672A2 (en) Leukotriene antagonists for oral squamous cell carcinoma
ATE245623T1 (en) COMPOUNDS WITH CYTOPROTECTION ACTION
TR199901307T2 (en) Lycotriene antagonists for oral squamous cell carcinoma
AR026901A1 (en) PEPTIDES WITH N-RENT THAT HAVE ANTIANGIOGEN ACTIVITY
EA200300468A1 (en) SUPPRESSION OF TUMOR CELL DEPENDENCE ON THE GROWTH FACTOR
DE3873278D1 (en) ARYL-SUBSTITUTED THIOPHEN-3-OLE, THEIR DERIVATIVES AND ANALOGS AS LIPOXYGENASE INHIBITORS.
TR200102576T2 (en) Radioactive cisplatin in cancer treatment
ID29101A (en) COMPOSITION THAT CONTAINS BITUMENTS IN THE FORM OF GRAIN
WO1999045951A3 (en) Thy-1 expression in angiogenesis
DE59914883D1 (en) SHUT-OFF THYRISTOR
TR200000254A2 (en) O-substituted hydroxyumaranone derivatives as antitumor and antimetastasis agents